TW202104215A - Ｊａｋ１選擇性激酶抑制劑 - Google Patents
Ｊａｋ１選擇性激酶抑制劑 Download PDFInfo
- Publication number
- TW202104215A TW202104215A TW109112994A TW109112994A TW202104215A TW 202104215 A TW202104215 A TW 202104215A TW 109112994 A TW109112994 A TW 109112994A TW 109112994 A TW109112994 A TW 109112994A TW 202104215 A TW202104215 A TW 202104215A
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- equivalent
- methoxy
- amino
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019083376 | 2019-04-19 | ||
| WOPCT/CN2019/083376 | 2019-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202104215A true TW202104215A (zh) | 2021-02-01 |
Family
ID=72837031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109112994A TW202104215A (zh) | 2019-04-19 | 2020-04-17 | Ｊａｋ１選擇性激酶抑制劑 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220220096A1 (enExample) |
| EP (1) | EP3956322B1 (enExample) |
| JP (1) | JP7555959B2 (enExample) |
| KR (1) | KR20220003537A (enExample) |
| CN (1) | CN113710664B (enExample) |
| AR (1) | AR118729A1 (enExample) |
| AU (1) | AU2020258619B2 (enExample) |
| BR (1) | BR112021020964A2 (enExample) |
| CA (1) | CA3134174A1 (enExample) |
| DK (1) | DK3956322T3 (enExample) |
| ES (1) | ES3031576T3 (enExample) |
| MX (1) | MX2021012749A (enExample) |
| PT (1) | PT3956322T (enExample) |
| TW (1) | TW202104215A (enExample) |
| WO (1) | WO2020211839A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7613778B2 (ja) * | 2020-11-26 | 2025-01-15 | 科輝智薬（深▲セン▼）新薬研究中心有限公司 | アミド化合物、医薬組成物およびその使用 |
| CN114380806B (zh) * | 2022-03-24 | 2022-06-10 | 中国药科大学 | 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用 |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| EP4554931A1 (en) * | 2022-07-12 | 2025-05-21 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9198900B2 (en) * | 2011-11-10 | 2015-12-01 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Treatment of peritoneal injury using JAK inhibitors |
| JP6767491B2 (ja) * | 2015-09-25 | 2020-10-14 | ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド | Ｊａｋを阻害するための化合物及び方法 |
| HRP20230069T1 (hr) * | 2017-01-17 | 2023-03-17 | Astrazeneca Ab | Selektivni inhibitori jak1 |
| WO2020057669A1 (zh) * | 2018-09-21 | 2020-03-26 | 上海轶诺药业有限公司 | 一类具有激酶抑制活性的芳香杂环类化合物 |
-
2020
- 2020-04-17 TW TW109112994A patent/TW202104215A/zh unknown
- 2020-04-17 AR ARP200101101A patent/AR118729A1/es unknown
- 2020-04-17 JP JP2021561927A patent/JP7555959B2/ja active Active
- 2020-04-17 ES ES20790639T patent/ES3031576T3/es active Active
- 2020-04-17 CA CA3134174A patent/CA3134174A1/en active Pending
- 2020-04-17 PT PT207906397T patent/PT3956322T/pt unknown
- 2020-04-17 CN CN202080029899.3A patent/CN113710664B/zh active Active
- 2020-04-17 AU AU2020258619A patent/AU2020258619B2/en active Active
- 2020-04-17 KR KR1020217036576A patent/KR20220003537A/ko not_active Ceased
- 2020-04-17 EP EP20790639.7A patent/EP3956322B1/en active Active
- 2020-04-17 MX MX2021012749A patent/MX2021012749A/es unknown
- 2020-04-17 US US17/604,442 patent/US20220220096A1/en active Pending
- 2020-04-17 DK DK20790639.7T patent/DK3956322T3/da active
- 2020-04-17 BR BR112021020964A patent/BR112021020964A2/pt unknown
- 2020-04-17 WO PCT/CN2020/085338 patent/WO2020211839A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES3031576T3 (en) | 2025-07-09 |
| EP3956322A1 (en) | 2022-02-23 |
| US20220220096A1 (en) | 2022-07-14 |
| PT3956322T (pt) | 2025-06-04 |
| EP3956322B1 (en) | 2025-05-14 |
| KR20220003537A (ko) | 2022-01-10 |
| WO2020211839A1 (en) | 2020-10-22 |
| BR112021020964A2 (pt) | 2021-12-14 |
| JP2022529061A (ja) | 2022-06-16 |
| CA3134174A1 (en) | 2020-10-22 |
| CN113710664A (zh) | 2021-11-26 |
| AR118729A1 (es) | 2021-10-27 |
| DK3956322T3 (da) | 2025-06-16 |
| JP7555959B2 (ja) | 2024-09-25 |
| AU2020258619B2 (en) | 2025-10-23 |
| MX2021012749A (es) | 2021-11-18 |
| CN113710664B (zh) | 2024-01-26 |
| EP3956322A4 (en) | 2023-05-03 |
| AU2020258619A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3956322B1 (en) | Jak1 selective kinase inhibitor | |
| US10640503B2 (en) | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | |
| CN111433200B (zh) | 用于治疗疾病的化合物及其药物组合物 | |
| US10125133B2 (en) | Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors | |
| TWI704152B (zh) | 作為ｊａｋ激酶抑制劑之萘啶化合物 | |
| US9695180B2 (en) | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | |
| TWI591067B (zh) | 吡唑并吡啶及吡唑并嘧啶 | |
| CN103649089B (zh) | 作为pi3k抑制剂的吡咯并三嗪酮 | |
| JP2015533181A (ja) | Ｐｉ３ｋ阻害剤としてのピロロトリアジノン誘導体 | |
| TW201446767A (zh) | 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物 | |
| US20230416268A1 (en) | Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors | |
| EP3947384B1 (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| RU2818002C2 (ru) | Селективный ингибитор киназы JAK1 | |
| HK40055987A (en) | Jak1 selective kinase inhibitor | |
| HK40055987B (zh) | Jak1选择性激酶抑制剂 | |
| US20240092791A1 (en) | Dihydrofuropyridine derivatives as rho-kinase inhibitors | |
| CN119968375A (zh) | 作为Janus激酶抑制剂的杂环衍生物 | |
| HK40057264A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors |